Predict your next investment

BenevolentAI company logo
Corporation
SOFTWARE (NON-INTERNET/MOBILE) | Healthcare Software
benevolent.com

See what CB Insights has to offer

Founded Year

2013

Stage

Incubator/Accelerator | Alive

Total Raised

$345.55M

About BenevolentAI

BenevolentAI creates and applies AI and machine learning to update the way medicines are discovered and developed. Benevolent integrates its technology into every step of the drug discovery process from hypothesis generation to late-stage clinical development.

BenevolentAI Headquarter Location

Maple Street, 4-8

London, England, W1T 5HD,

United Kingdom

+44 (0) 20 3096 0720

Latest BenevolentAI News

BenevolentAI Identifies Novel Target For Ulcerative Colitis And Advances Candidate To IND/CTA-enabling Studies

Oct 14, 2021

BenevolentAI Identifies Novel Target For Ulcerative Colitis And Advances Candidate To IND/CTA-enabling Studies - The Benevolent PlatformTM for AI-driven drug discovery identified and validated a novel biological target not previously linked to the disease Author: LONDON, Oct. 14, 2021 /PRNewswire/ -- In a significant milestone for its (AI)-driven drug discovery platform, BenevolentAI has nominated a preclinical candidate for a novel ulcerative colitis target, and plans to advance the asset into clinical trials. Scientists deployed BenevolentAI's powerful target ID tools and machine learning models to identify and experimentally validate a novel biological target with no prior reference in published literature or patents linking the gene to ulcerative colitis. BenevolentAI used its advanced molecular design capabilities to generate a potential best-in-class, oral, peripherally restricted candidate drug within two years of target validation. The preclinical candidate has been experimentally validated in ex-vivo ulcerative colitis colon samples from patients who were unresponsive to the standard of care treatment. BenevolentAI plans to move the programme into the clinic in early 2023. The company is currently applying its precision medicine AI models to inform clinical trial design, trained on ulcerative colitis patient data to target key responder patient cohorts and identify efficacy biomarkers. Anne Phelan, Chief Scientific Officer at BenevolentAI, commented, "Ulcerative colitis is a chronic, lifelong disease that affects 0.2% of the US population alone and 1.6 million patients in the 7 major markets, yet it is poorly served by the standard of care therapies. Our novel preclinical candidate addresses the high unmet need for an oral, safe and efficacious therapy and has demonstrated improved safety and tolerability profile compared with other leading IBD treatments. We are actively using patient-derived molecular descriptors to target patient subgroups that will optimise trial design and further increase our probability of success." Joanna Shields, Chief Executive Officer of BenevolentAI, commented, "Nominating a drug candidate for a novel ulcerative colitis target identified by our AI-drug discovery platform represents a milestone for BenevolentAI but more importantly, advances a new potential treatment for this debilitating disease." This latest milestone in ulcerative colitis further validates Benevolent's AI Platform and drug discovery expertise in identifying novel targets for complex multifactorial diseases. In early 2021, a novel AI-generated target was selected for AstraZeneca's portfolio in CKD, with further targets expected in IPF. The ulcerative colitis programme sits within a rapidly scaling pipeline of over 20 in-house programmes, including an asset in clinical trial s for atopic dermatitis. The company also discovered Eli Lilly's baricitinib as a treatment for COVID-19 - a novel drug repurposing hypothesis that is now clinically validated and FDA Approved . As of 2021, BenevolentAI is the only AI-augmented drug discovery company whose drug discovery platform and approach has been validated computationally, experimentally and in the clinic. About BenevolentAI BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 20+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, discovering a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic. Contact: Rajin Kang rajin.kang@benevolent.ai +44(0)7732 603 108 View original content: https://www.prnewswire.com/news-releases/benevolentai-identifies-novel-target-for-ulcerative-colitis-and-advances-candidate-to-indcta-enabling-studies-301400124.html

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing BenevolentAI

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned BenevolentAI in 3 CB Insights research briefs, most recently on Sep 30, 2021.

Expert Collections containing BenevolentAI

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

BenevolentAI is included in 6 Expert Collections, including Unicorns- Billion Dollar Startups.

U

Unicorns- Billion Dollar Startups

863 items

A

Artificial Intelligence ( AI ) in Healthcare

826 items

These healthcare startups are using AI to discover new drugs, remotely monitor patients, securely transfer patient data, and more.

H

Healthcare Horizons

27 items

Cutting-edge developments in healthcare, and the startups behind them, that are just beginning to impact the world. This collection includes companies covered in the Healthcare Horizons briefing and accompanying report.

F

Future of Pharma R&D

62 items

A

Artificial Intelligence

7,394 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

B

Biopharmaceuticals

14,138 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

BenevolentAI Patents

BenevolentAI has filed 21 patents.

The 3 most popular patent topics include:

  • Machine learning
  • Bioinformatics
  • Biological databases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/17/2019

6/22/2021

Clusters of differentiation, Cytokines, Inflammations, Transcription factors, Proteins

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

7/17/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

6/22/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Clusters of differentiation, Cytokines, Inflammations, Transcription factors, Proteins

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

BenevolentAI Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

BenevolentAI Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.